Despite the fact that targeting the OPG/RANK/RANKL pathway is a promising therapeutic strategy for breast tumors, this approach seems to be limited by the critical role of this pathway in bone remodeling, and other physiological processes. The gene discussed is TNFRSF11B; the disease is breast neoplasm.